Cargando…
Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer
BACKGROUND: Breast cancer (BC) is the most common cancer in women, and despite the introduction of new screening programmes, therapies and monitoring technologies, there is still a need to develop more useful tests for monitoring treatment response and to inform clinical decision making. The purpose...
Autores principales: | Fernandez-Garcia, Daniel, Hills, Allison, Page, Karen, Hastings, Robert K., Toghill, Bradley, Goddard, Kate S., Ion, Charlotte, Ogle, Olivia, Boydell, Anna Rita, Gleason, Kelly, Rutherford, Mark, Lim, Adrian, Guttery, David S., Coombes, R. Charles, Shaw, Jacqueline A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924016/ https://www.ncbi.nlm.nih.gov/pubmed/31856868 http://dx.doi.org/10.1186/s13058-019-1235-8 |
Ejemplares similares
-
Comparison of phenomics and cfDNA in a large breast screening population: the Breast Screening and Monitoring Study (BSMS)
por: Stebbing, Justin, et al.
Publicado: (2023) -
Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
por: Fairclough, Stephen R., et al.
Publicado: (2019) -
Microfluidic Technologies for cfDNA Isolation and Analysis
por: Xu, Zheyun, et al.
Publicado: (2019) -
Combinatorial Power of cfDNA, CTCs and EVs in Oncology
por: Keup, Corinna, et al.
Publicado: (2022) -
cfDNA Sequencing: Technological Approaches and Bioinformatic Issues
por: Bohers, Elodie, et al.
Publicado: (2021)